SCHEMBL498199

SCHEMBL498199

C=Cc1cccc(C(=O)OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 5/20 0.56
GRIN2D O15399 1/20 0.56
GRIN3B O60391 1/20 0.56
GRIN1 Q05586 1/20 0.56
GRIN2A Q12879 1/20 0.56
GRIN2B Q13224 1/20 0.56
GRIN2C Q14957 1/20 0.56
GRIN3A Q8TCU5 1/20 0.56
TSHR P16473 1/20 0.52
LOXL2 Q9Y4K0 1/20 0.51
CYP4F2 P78329 2/20 0.50
CYP4A11 Q02928 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
RAB9A P51151 2/20 0.49
POLB P06746 1/20 0.49
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
ERN1 O75460 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11222093 0.85 P4HB (0.68) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4407110 0.85 P4HB (0.68) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2904118 0.85 UNG (0.44) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11456160 0.85 P4HB (0.59) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL129107 0.84 P4HB (0.57) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL47068 0.84 ALDH1A1 (0.61) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL16618968 0.84 P4HB (0.57) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29677467 0.84 ALDH1A1 (0.61) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL9391831 0.83 P4HB (0.58) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL9277103 0.83 P4HB (0.51) P4HBGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3051946-B1 USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS BAYER CROPSCIENCE AG (DE) 2017-11-29 EP claimed
EP-3051946-A1 USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS Bayer CropScience Aktiengesellschaft (DE) 2016-08-10 EP claimed
WO-2015049351-A1 USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS BAYER CROPSCIENCE AG (DE) 2015-04-09 WO claimed
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
CN-120136646-A Method for synthesizing benzyl alkyl ketone compound by visible light catalysis 中国科学院化学研究所 2025-06-13 CN disclosed
EP-4400503-A2 NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2024-07-17 EP disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
EP-3246070-B1 NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING AZOLES GILEAD SCIENCES INC (US) 2024-03-20 EP disclosed
US-11858889-B2 Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease THE TRUSTEES OF INDIANA UNIVERSITY (US) 2024-01-02 US disclosed
US-11858889-B2 Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease THE TRUSTEES OF INDIANA UNIVERSITY (US) 2024-01-02 US disclosed
US-11858889-B2 Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease THE TRUSTEES OF INDIANA UNIVERSITY (US) 2024-01-02 US disclosed
US-5322847-A Inhibit platelet activating factor, block leukotriene D4 receptors PFIZER INC. (US) 1994-06-21 US disclosed
EP-0379191-B1 1,3-Dioxolane benzoic acids and derivatives thereof SEARLE & CO (US) 1994-01-19 EP disclosed
US-5242930-A AZABICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY MERCK SHARP & DOHME LTD. 1993-09-07 US disclosed
EP-0533695-A1 IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY. PFIZER (US) 1993-03-31 EP disclosed
EP-0499313-A1 Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy MERCK SHARP & DOHME LTD. (GB) 1992-08-19 EP disclosed
WO-1991017163-A1 IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY PFIZER INC. (US) 1991-11-14 WO disclosed
US-4954520-A 1,3-dioxolane derivatives useful in the treatment of inflammation G. D. SEARLE & CO. (US) 1990-09-04 US disclosed
EP-0379191-A1 1,3-Dioxolane benzoic acids and derivatives thereof G.D. Searle & Co. (US) 1990-07-25 EP disclosed
US-3932573-A Process for producing glass fiber reinforced injection molding compounds ETHYL CORPORATION (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB P4HB 3554/4885GRIN2D 3835/4885GRIN3B 3538/4885
US-11858889-B2 Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease ADM2, DDAH1, BHMT P4HB 910/4885GRIN2D 2665/4885GRIN3B 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.